若您需要咨询产品或有任何技术问题,请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。

冻存的人外周血CD4+ T细胞

冻存的人原代细胞
只有 %1
¥0.00

产品号 #(选择产品)

产品号 #70026_C

冻存的人原代细胞

Save on high-quality cells! Take advantage of our bulk pricing discounts and price matching offer to get the best value for your purchase. Browse our Frequently Asked Questions for more information.

概览

原代人CD4+ T细胞通过使用免疫磁珠负选技术从外周血(PB)单个核细胞(MNCs)中分离获得。PB使用抗凝剂酸性柠檬酸葡萄糖溶液AACDA)收集。

细胞使用机构审查委员会(IRB)批准的同意书和方案获取。某些产品仅在特定国家/地区提供。

某些产品仅在特定国家/地区提供。请联系您当地的销售代表或产品与科学支持部门(邮箱:techsupport.cn@stemcell.com)以获取更多信息。

浏览我们关于原代细胞的常见问题解答(FAQs

 

包含
• CryoStor® CS10

分类
冻存

细胞类型
T 细胞CD4+ T细胞

物种

细胞和组织来源
外周血

研究领域
药物发现和毒性检测

供体状态
正常

纯度
≥ 85% CD4+(通过流式分析检测)

 

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明,或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
70026, 200-0165
Lot #
All
Language
English

应用领域

本产品专为以下研究领域设计,适用于工作流程中的高亮阶段。探索这些工作流程,了解更多我们为各研究领域提供的其他配套产品。

相关材料与文献

技术资料 (4)

文献 (2)

Isoform-selective activity-based profiling of ERK signaling. M. Shin et al. Chemical science 2018 MAR

Abstract

Extracellular signal-regulated kinases (ERKs) mediate downstream signaling of RAS-RAF-MEK as key regulators of the mitogen-activated protein kinase (MAPK) pathway. Activation of ERK signaling is a hallmark of cancer and upstream MAPK proteins have been extensively pursued as drug targets for cancer therapies. However, the rapid rise of resistance to clinical RAF and MEK inhibitors has prompted interest in targeting ERK (ERK1 and ERK2 isoforms) directly for cancer therapy. Current methods for evaluating activity of inhibitors against ERK isoforms are based primarily on analysis of recombinant proteins. Strategies to directly and independently profile native ERK1 and ERK2 activity would greatly complement current cell biological tools used to probe and target ERK function. Here, we present a quantitative chemoproteomic strategy that utilizes active-site directed probes to directly quantify native ERK activity in an isoform-specific fashion. We exploit a single isoleucine/leucine difference in ERK substrate binding sites to enable activity-based profiling of ERK1 versus ERK2 across a variety of cell types, tissues, and species. We used our chemoproteomic strategy to determine potency and selectivity of academic (VX-11e) and clinical (Ulixertinib) ERK inhibitors. Correlation of potency estimates by chemoproteomics with anti-proliferative activity of VX-11e and Ulixertinib revealed that {\textgreater}90{\%} inactivation of both native ERK1 and ERK2 is needed to mediate cellular activity of inhibitors. Our findings introduce one of the first assays capable of independent evaluation of native ERK1 and ERK2 activity to advance drug discovery of oncogenic MAPK pathways.
Evidence of an oncogenic role of aberrant TOX activation in cutaneous T-cell lymphoma. Huang Y et al. Blood 2015 FEB

Abstract

TOX is a nuclear factor essential for the development of CD4(+) T cells in the thymus. It is normally expressed in low amounts in mature CD4(+) T cells of the skin and the peripheral blood. We have recently discovered that the transcript levels of TOX were significantly increased in mycosis fungoides, the most common type of cutaneous T-cell lymphoma (CTCL), as compared to normal skin or benign inflammatory dermatoses. However, its involvement in advanced CTCL and its biological effects on CTCL pathogenesis have not been explored. In this study, we demonstrate that TOX expression is also enhanced significantly in primary CD4(+)CD7(-) cells from patients with Sézary syndrome, a leukemic variant of CTCL, and that high TOX transcript levels correlate with increased disease-specific mortality. Stable knockdown of TOX in CTCL cells promoted apoptosis and reduced cell cycle progression, leading to less cell viability and colony-forming ability in vitro and to reduced tumor growth in vivo. Furthermore, TOX knockdown significantly increased 2 cyclin-dependent kinase (CDK) inhibitors, CDKN1B and CDKN1C. Lastly, blocking CDKN1B and CDKN1C reversed growth inhibition of TOX knockdown. Collectively, these findings provide strong evidence that aberrant TOX activation is a critical oncogenic event for CTCL.

更多信息

更多信息
物种 人类
Contains • CryoStor® CS10
纯度 ≥ 85% CD4+ by flow cytometry
细胞与组织来源 外周血
捐献者身份 正常
质量保证:

产品仅供研究使用,不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息,请访问 STEMCELL.CN/COMPLIANCE.
Copyright © 2026 by STEMCELL Technologies. All rights reserved.

在线联系